Short summary: Aequs Limited — a vertically integrated precision & contract manufacturer with a meaningful footprint in aerospace and engineering manufacturing — is launching a large book-built IPO from Dec 3–5, 2025. Price band, lot size, issue size, GMP and other key details below, followed by a concise review and listing expectations.
Key facts (what every investor wants to know)
- Issue open: December 3, 2025 — closes December 5, 2025.
- Price band: ₹118 – ₹124 per equity share (face value ₹10).
- Lot size (minimum application): 120 shares per lot (minimum retail ticket ≈ ₹14,880 at upper band).
- Issue size (total): ~₹921.8 crore (mix of fresh issue and Offer For Sale). Fresh / OFS split reported in sources (fresh portion ~₹670 crore; OFS ~₹251.8 crore).
- Reservation: Reported split — QIB 75% / HNI 15% / Retail 10% (confirm on RHP for exact wording).
- Tentative listing date: Market reports indicate a tentative listing around Dec 10, 2025 (check exchange notices for final date).
- Registrar: KFin Technologies Ltd (reported).
- Book running / lead managers: Listed in filings and abridged prospectus (see RHP & lead manager PDFs).
Grey Market Premium (GMP)
Grey-market chatter ahead of subscription shows strong positive sentiment:
- Multiple market trackers and business outlets report GMPs in the ₹30–₹43 range (which implies expected listing gains of roughly 20–35% over the upper price band of ₹124 if GMP translates to listing). Examples: reports citing ₹30, ₹42, ₹43 across different trackers today.
Takeaway on GMP: GMP is a secondary, unofficial indicator driven by short-term sentiment and speculation. It can swing sharply before listing. Use GMP as one data point — not a substitute for fundamentals or your own risk tolerance.
Business — what Aequs does
- Aequs is a contract/precision manufacturer with integrated capabilities for aerospace components and consumer/industrial segments. It emphasizes vertically integrated manufacturing for complex components (a reason investors often reward such companies with premium multiples). The RHP and abridged prospectus provide operational, segment and promoter background.
Financials & use of proceeds
- The company has filed its RHP / abridged prospectus with SEBI; fresh issue proceeds are earmarked for growth capex, working capital and general corporate purposes (see RHP for exact allocation and the detailed numbers). Readers should inspect the RHP for FY revenue / margin trends, segmental contribution and balance-sheet metrics before bidding.
Strengths (why GMP / interest may be high)
- Aerospace exposure: Aerospace components (a high-value, technical manufacturing segment) often command superior order visibility and repeat business.
- Vertically integrated model: Reduces supply chain risk and can improve margins if scale is achieved.
- Large issue size, good market timing: A large IPO and visible promoters/backers can attract institutional interest (reflected in reported QIB skew).
Risks & caution points
- GMP vs reality: Grey market premiums are not guaranteed listing prices; they reflect short-term demand and can reverse.
- Capital intensity / cyclical demand: Manufacturing and aerospace are capital-intensive and can face cyclical order flows and margin pressure. Check backlog and order book quality in the RHP.
- High institutional allocation: With a reported 75% QIB quota, retail allotment may be limited — retail investors may face allotment risk even if the issue is well-subscribed.
Valuation & listing outlook
- At upper band (₹124): If GMP reports ~₹30–₹43 hold, implied listing price could be ₹154–₹167 (≈ 24%–35% uplift from ₹124). But remember: GMP moves and listing discovery price is set by demand at listing.
- Institutional appetite matters more than GMP: Given the IPO’s large size and heavy QIB portion, institutional demand during the book-building process will be the critical determinant of pricing pressure and final subscription, more so than grey market chatter.
Practical investor checklist (before you bid)
- Read the RHP / abridged prospectus (SEBI / registrar pages). Confirm use of proceeds, related-party exposures, and segmental revenue mix.
- Check price band and compute your minimum ticket (120 shares). Confirm you’re comfortable with the minimum outlay.
- Decide allocation preference (apply in retail or HNI/QIB as appropriate) — allotment probabilities differ across categories.
- Treat GMP as a sentiment signal only; make the bid based on fundamentals, your time-horizon and risk tolerance.
Closing
Aequs is highly anticipated (strong grey-market interest and a sizeable institutional allocation). If you’re a long-term investor attracted to a vertically integrated aerospace/precision manufacturer, the company merits a close read of the RHP and financials. If you’re a short-term trader, GMP indicates potential listing upside but also higher volatility — proceed only with clear exit rules.
Not investment advice. Always confirm final IPO prospectus/RHP details and consult a financial advisor for suitability.